As of 14 Oct 2026, Mirador Therapeutics has raised $250M across 1 verified round on record; latest: $250 million Series B, announced 12 Jan 2026.
Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases.
miradortx.comSan Diego, CA
1 source
The release also reports more than $650 million in total capital raised since launch; that is cumulative capital, not the Series B amount.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $250M $650M to date | 2026-01-12 | not stated | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source The release also reports more than $650 million in total capital raised since launch; that is cumulative capital, not the Series B amount. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: businesswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage | ||||